CYDY · XBRL financial data
CytoDyn financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (CYDY's year ends in late May)
| In millions of dollars | May 31, 2021 | May 31, 2022 | May 31, 2023 | May 31, 2024 | May 31, 2025 | May 31, 2026 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 0 | 0 | 0 | — | — | — |
| Cost of revenue | — | 0 | — | — | — | — |
| Gross profit | — | 0 | — | — | — | — |
| Research and development | 58 | 27 | 3 | 7 | — | — |
| General and administrative | 34 | 44 | 17 | 11 | 7 | 7 |
| Operating income (loss) | (105) | (145) | (41) | (18) | 10 | (39) |
| Interest income | 0 | — | — | 0 | 1 | 0 |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (155) | (211) | (80) | (50) | 4 | (43) |
| Earnings per share, basic USD per share | (0.30) | (0.31) | (0.10) | (0.05) | 0.00 | (0.03) |
| Earnings per share, diluted USD per share | (0.30) | (0.31) | (0.10) | (0.05) | 0.00 | (0.03) |
| Weighted average shares, basic millions of shares | 588 | 677 | 837 | 970 | 1,206 | 1,289 |
| Weighted average shares, diluted millions of shares | 588 | 677 | 837 | 970 | 1,243 | 1,289 |
Balance sheet
CSVFiscal years (CYDY's year ends in late May)
| In millions of dollars | May 31, 2021 | May 31, 2022 | May 31, 2023 | May 31, 2024 | May 31, 2025 | May 31, 2026 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 34 | 4 | 3 | 3 | 12 | 12 |
| Inventory | 93 | — | 0 | 0 | — | — |
| Total current assets | 130 | 11 | 11 | 11 | 18 | 14 |
| Property and equipment, net | 0 | 0 | — | — | — | — |
| Right-of-use asset | 1 | 1 | 0 | 0 | 0 | 0 |
| Total assets | 132 | 29 | 11 | 11 | 18 | 14 |
| Accounts payable | 66 | 68 | 63 | 30 | 15 | 13 |
| Total current liabilities | 153 | 123 | 120 | 84 | 71 | 54 |
| Lease liability, non-current | 1 | 0 | 0 | 0 | 0 | 0 |
| Total liabilities | 153 | 124 | 121 | 128 | 114 | 124 |
| Accumulated deficit | (511) | (766) | (842) | (892) | (888) | (930) |
| Total stockholders' equity | (21) | (94) | (110) | (117) | (96) | (110) |
| Total liabilities and equity | 132 | 29 | 11 | 11 | 18 | 14 |
| Common shares outstanding (cover page) millions of shares | 633 | 811 | 931 | 1,215 | 1,252 | 1,382 |
Cash flows
CSVFiscal years (CYDY's year ends in late May)
| In millions of dollars | May 31, 2021 | May 31, 2022 | May 31, 2023 | May 31, 2024 | May 31, 2025 | May 31, 2026 |
|---|---|---|---|---|---|---|
| Net income (loss) | (155) | (211) | (80) | (50) | 4 | (43) |
| Stock-based compensation | 10 | 6 | 4 | 2 | 2 | 2 |
| Net cash from operating activities | (118) | (78) | (25) | (11) | (9) | (17) |
| Purchases of property and equipment | 0 | — | — | — | — | — |
| Net cash from investing activities | (0) | — | — | — | 0 | 0 |
| Proceeds from issuing common stock | — | — | — | — | — | 1 |
| Repayments of long-term debt | 1 | — | — | — | — | — |
| Net cash from financing activities | 137 | 48 | 30 | 12 | 11 | 17 |
| Net change in cash | 20 | (30) | 5 | 1 | 2 | (0) |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| CytoDyn | 16 | not reported | (7.7) | 1.5B | 2.1 quarters | 10-QAug 31, 2026 |
| Cryoport | 269 | 49 | 1.1* | 50.6M | — | 10-QJun 30, 2026 |
| Capricor Therapeutics | 21 | not reported | (31)* | 58.1M | 7.6 quarters | 10-QJun 30, 2026 |
| Theravance Biopharma | 220 | 21 | (7)* | 51.9M | 55.7 quarters | 10-QJun 30, 2026 |
| REGENXBIO | 36 | 108 | (62)* | 66.0M | 1.7 quarters | 10-QJun 30, 2026 |
| Zevra Therapeutics | 122 | 38 | 10* | 59.5M | — | 10-QSep 30, 2026 |
| Cronos Group | 467 | 53 | 24* | 368.4M | — | 10-QJun 30, 2026 |
| aTYR PHARMA | 16 | not reported | (9.4)* | 98.1M | 6.1 quarters | 10-QJun 30, 2026 |
| CytomX Therapeutics | 17 | 1.4 | (18)* | 217.9M | 18.3 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.